Scott Clarke, Tizona CEO (Tizona)

Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

The Gilead BD team has teed up an­oth­er on­col­o­gy deal for CEO Dan O’Day.

This time the big biotech is rolling out a $300 mil­lion cash in­vest­ment in Tizona Ther­a­peu­tics in South San Fran­cis­co, buy­ing up 49.9% of the com­pa­ny and re­serv­ing up to $1.25 bil­lion more to swal­low the whole en­chi­la­da if the biotech’s am­bi­tious Phase I pro­gram for their HLA-G drug TTX-080 pans out as hoped for.

The deal is square­ly fo­cused on this one drug, which Tizona CEO Scott Clarke has billed as a bright new hope for treat­ing tu­mors that es­cape the cur­rent gen­er­a­tion of PD-(L)1 drugs in or near the mar­ket. And it’s not their lead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.